Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix and keeping the price target at $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yi Chen’s rating is based on several promising developments for Ocular Therapeutix. The company has secured a Special Protocol Assessment (SPA) agreement with the FDA for its registrational trial design in non-proliferative diabetic retinopathy (NPDR), which provides a clear regulatory path forward. In previous trials, AXPAXLI demonstrated significant efficacy by preventing disease progression in NPDR patients, highlighting its potential as a once-a-year treatment option that could shift the current treatment paradigm.
Additionally, Ocular Therapeutix is making progress with its Phase 3 SOL-1 trial for wet age-related macular degeneration (AMD), with topline results expected in the first quarter of 2026. The company has also completed enrollment for the SOL-R trial and streamlined rescue criteria, aligning them with real-world practices, which could enhance market adoption if approved. These strategic advancements and the potential market impact of AXPAXLI support Yi Chen’s Buy rating and the $15 price target for the stock.